GVB Biopharma Takes Control as Industry Leader in Cannabis

Business by 2FIRSTS.ai

Jan.04.2024

GVB Biopharma Takes Control as Industry Leader in Cannabis

Leading industrial hemp and cannabis industry company, GVB Biopharma, announced its return to private ownership effective December 28, 2023.

According to a report by the United States Press Agency on January 3rd, leading industrial hemp and cannabis industry enterprise GVB Biopharma announced that as of December 28, 2023, the company will be under the leadership of its founding team once again.

GVB Biopharma has consistently been at the forefront of the industry with its cutting-edge low-temperature cannabis extraction, refinement, conversion, and advanced product formulation technologies. As a leading supplier of cannabinoids, GVB Biopharma is committed to maintaining the reputation of its high-quality and highly regarded products. The company has successfully reverted to being a privately-owned entity, allowing it to be more flexible in adapting to the changes in the global cannabis market in the future.

Chief Executive Officer Drew Spiegel has expressed, "As the cannabis industry continues to mature, our vision and capabilities align perfectly with market trends. Under our commitment to quality, innovation, and esteemed clientele, we are thrilled to be at the forefront of the next phase of industry growth.

References:

[1] GVB Biopharma Taken Private, Poised for Continued Growth in Hemp and Cannabis Industry

Also Read:

[1] Argentinian National Gendarmerie Discovers 5-Ton Marijuana Haul

[2] 22nd Century Group Announces Completion of Cannabis Business Sale

#North America #United States #CBD #E-cigarette Industry #Tobacco Control Plan #Cannabis vaporization

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Indonesian Police to Crack Down on Etomidate-Laced Vapes

Indonesia’s National Police Criminal Investigation Department (Bareskrim Polri) will continue to take enforcement action against users and distributors of etomidate-laced vape liquids, even though the substance is not yet classified as a narcotic. Brigadier General Eko Hadi Santoso, Director of Narcotics Crimes, said etomidate is an anaesthetic drug regulated under Health Law No. 17 of 2023, but has not been listed as a narcotic or psychotropic substance.

Oct.23 by 2FIRSTS.ai

Illegal Market Surges After Kazakhstan Bans E-Cigarettes; Telegram Becomes the Main Trading Channel

Since Kazakhstan banned e-cigarette sales in June 2024, transactions have gone underground, shifting to Telegram and some e-commerce platforms and making enforcement harder; related research indicates the ban has not significantly reduced demand.

Oct.20 by 2FIRSTS.ai

Altria’s on!PLUS Nicotine Pouches Reportedly Available in U.S.; Users Say They Have Received Orders

Social media users reported purchasing Altria’s new nicotine pouch, on!PLUS, in the United States. 2Firsts found that the official on! website had temporarily opened online purchase and store locator functions. The product has not received FDA authorization. Around the same time, British American Tobacco (BAT) suspended its unlicensed Vuse One vape launch in the U.S. amid regulatory pressure.

Oct.28 by 2FIRSTS.ai

From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market

As global competition in the nicotine pouch market accelerates, Korea’s tobacco major KT&G has moved with a “Partnership + Acquisition” strategy, teaming up with Altria to acquire Nordic pouch maker Another Snus Factory (brand “LOOP”). Why deploy capital now, and why take this route? Drawing on company disclosures, regulatory monitoring and on-site observations from InterTabac Dortmund, 2Firsts analyzes KT&G’s strategic calculus and the signals behind this move.